Physician
Cardiology
Dr. Bertram Pitt, MD
|
|
Give Review
Bertram Pitt works in the field of Cardiology. He over the years received 2 awards: "Fellow (FACC)" and "Whos Who in Medicine and Healthcare". Doctor Bertram Pitt, MD has written publications. He has 52 publications published with PubMed. The lastest paper is: 'Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Ant...'
Publications
- Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Ant...
- The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
- Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?
- Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an ana...
- Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
- Prognostic Value of Estimated Plasma Volume in Heart Failure.
- Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure.
- Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials.
- Emerging cardiovascular indications of mineralocorticoid receptor antagonists.
- Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients w...
- Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction.
- Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from r...
- Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and the Metabolic Syndrome.
- Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial.
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors.
- Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment of Preserved...
- Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease.
- Geographic variation in heart failure trials: time for scepticism?
- Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist.
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study.
- Spironolactone for heart failure with preserved ejection fraction.
- Developing Therapies for Heart Failure With Preserved Ejection Fraction: Current State and Future Directions.
- The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction.
- Decongestion in acute heart failure.
- Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segmen...
- The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27â610 patients.
- Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function.
- Opposite Predictive Value of Pulse Pressure and Aortic Pulse Wave Velocity on Heart Failure With Reduced Left Ventricular Ejection Fraction: Insights From an Eplerenon...
- Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients with Heart Failure Receiving the Mineralocorticoid Recept...
- Mineralocorticoid receptor antagonists in patients with end stage renal disease (ESRD ) on chronic hemodialysis.
- Complete Renin-Angiotensin-Aldosterone System (RAAS) Blockade in High-Risk Patients: Recent Insights From Renin Blockade Studies.
- The past, present and future of renin-angiotensin aldosterone system inhibition.
- Biomarker-guided therapies in heart failure: a forum for unified strategies.
- Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure.
- Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.
- Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and/or worsening renal function: Analyses of EMPHASIS-HF study subgroups.
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chroni...
- Soluble guanylate cyclase: a potential therapeutic target for heart failure.
- Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiti...
- Adverse events in HEAAL: when to hold and when to fold.
- Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evalu...
- The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure.
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
- Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study).
- The role of mineralocorticoid receptor antagonists in patients with american college of cardiology/american heart association stage B heart failure.
- Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial.
- Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction.
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
- Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
- Heart failure: the role for mineralocorticoid receptor antagonists.
Schools
University of Basel Medical Faculty
Beth Israel Hospital
Johns Hopkins Hospital
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Fellow (FACC)
- Whos Who in Medicine and Healthcare
Education
-
Johns Hopkins University -
Mount Sinai Beth Israel -
University of Basel Faculty of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Fred Morady, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark R. Benson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott L. Hummel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Bengtson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric R. Bates, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Monika Leja, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael H. Lehmann, MD |
|
|
Dr. Milton L. Pressler, MD |
|
|
Dr. Keith D. Aaronson, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jean-Francois Sarrazin, MD |
|
|
Dr. Amer K. Ardati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chin P. Chan, MD |
|
|
Dr. Maryse Palardy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Snehalkumar A. Patel, MD |
|
|
Dr. Colby R. Halsey, MD
This Doctor is OpenDoctor Recommended.
|